The results from the present study showed that, in a real-world primary care setting, the long-term use of GLP-1RAs and SGLT-2i in type 2 diabetes patients was associated with a significantly decreased risk of new-onset CKI (CKD at stages G3–G5). The gene discussed is CHKA; the disease is type 2 diabetes mellitus.